Most importantly, the downregulation of PHLDA1 in IMR-32 increased the level of tropomyosin receptor kinase B (TRKB), a marker of poor prognosis in neuroblastoma (Brodeur et al. 2009; Durbas et al. 2016). The gene discussed is PHLDA1; the disease is neuroblastoma.